San Diego-centered Viking Therapeutics marked by itself as a significant competitor from the weight loss drug current market in February immediately after revealing promising info from the mid-phase demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when supplied as a weekly injection As well as in